Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Sequel Med Tech and Arecor Partner to Advance Ultra-Concentrated Insulin Delivery

Sequel Med Tech, a leading medical device manufacturer, has announced a collaboration with Arecor Therapeutics to develop an innovative insulin delivery system. The partnership aims to combine Sequel's twiist insulin pump with Arecor's ultra-concentrated AT278 insulin, potentially revolutionizing diabetes management for patients requiring high daily doses.

NoahAI News9/26/2025

NIH Budget Cuts Could Severely Impact Future Drug Development, Study Finds

A new study published in Science reveals that proposed budget cuts to the National Institutes of Health (NIH) could have far-reaching consequences for drug development and patient care. The research, led by economist Pierre Azoulay of MIT, paints a sobering picture of how reduced federal funding might stifle innovation in the pharmaceutical industry.

NoahAI News9/26/2025

NIH Invests $87M in Organoid Center to Advance Drug Testing Alternatives

The National Institutes of Health (NIH) has taken a significant step towards reducing reliance on animal testing in drug development by allocating $87 million to establish the Standardized Organoid Modeling (SOM) Center. This initiative, announced on September 25, 2025, aims to accelerate drug discovery and translational science through the creation of standardized, reproducible, and accessible organoid models.

NoahAI News9/26/2025

Hansa Biopharma's Kidney Transplant Drug Imlifidase Shows Promise in Phase 3 Trial

Swedish biopharmaceutical company Hansa Biopharma has reported positive top-line results from its U.S. phase 3 trial of imlifidase, an antibody-cleaving enzyme designed to facilitate kidney transplants in highly sensitized patients with end-stage renal disease. The successful trial brings the company one step closer to potential FDA approval and U.S. market entry.

NoahAI News9/26/2025

Privia Health Expands Value-Based Care Footprint with $100M Acquisition of Evolent Health's ACO Business

Privia Health Group, a physician enablement company, has announced plans to acquire Evolent Health's accountable care organization (ACO) business for $100 million in cash, with potential for an additional $13 million based on 2025 Medicare Shared Savings Program (MSSP) performance. The deal, expected to close by the end of this year, significantly expands Privia's value-based care (VBC) presence and is anticipated to contribute positively to adjusted EBITDA in 2026.

NoahAI News9/26/2025

Cancer Pain Management: A Complex Challenge for Patients and Researchers

Cancer patients are living longer than ever thanks to breakthroughs in drug research, but many continue to struggle with debilitating pain. Despite the large number of patients affected - between 20% and 50% of cancer patients experience related pain - pharmaceutical companies have largely shied away from developing new pain therapies.

NoahAI News9/26/2025

Leadership Changes and Strategic Moves Reshape Pharmaceutical Landscape

In a series of significant leadership changes and strategic appointments, several major players in the pharmaceutical and biotech industries are positioning themselves for future growth and innovation. These moves come at a time of increasing geopolitical tensions and technological advancements, highlighting the industry's need for experienced leadership to navigate complex challenges.

NoahAI News9/26/2025

Datavant Expands Health Data Capabilities with DigitalOwl Acquisition

Datavant, a leading health technology company, has announced plans to acquire DigitalOwl, an Israeli startup specializing in AI-powered medical record analysis. This strategic move marks Datavant's third acquisition in recent months, following the purchases of Ontellus and Aetion.

NoahAI News9/26/2025

Reckitt Launches $13.3 Million Social Impact Investment Program in the US, Partners with Serena Williams

Reckitt, the UK-based company behind household brands Lysol and Mucinex, has unveiled a new social impact investment program called Catalyst in the United States. The initiative represents a five-year commitment to provide £10 million ($13.3 million) in funding and mentorship opportunities for early-stage companies and underrepresented founders in the health and hygiene sector.

NoahAI News9/26/2025

Lilly Halts Mid-Stage Obesity Study, Shifts Focus in Weight Loss Market

Eli Lilly has announced the discontinuation of its Phase IIb trial evaluating bimagrumab, an investigational antibody, in combination with its weight loss drug Zepbound (tirzepatide). The decision, attributed to "strategic business reasons" according to a federal clinical trials database, marks a significant shift in the company's approach to obesity treatment.

NoahAI News9/25/2025

Capricor's Duchenne Cell Therapy Gains New Life with FDA Reconsideration

Capricor Therapeutics has received a promising signal from the U.S. Food and Drug Administration (FDA) regarding its experimental cell therapy for Duchenne muscular dystrophy, potentially reversing a previous rejection. The company's renewed optimism comes after a recent meeting with FDA officials, who indicated willingness to reconsider the application for deramiocel with new data from an ongoing clinical trial.

NoahAI News9/25/2025

Merck KGaA Announces CEO Transition Amid Geopolitical Tensions and Industry Shifts

German healthcare and electronics conglomerate Merck KGaA has announced a significant leadership change, with current CEO Belén Garijo set to step down at the end of April 2026. This transition comes at a time of increasing geopolitical tensions and evolving dynamics in the pharmaceutical and semiconductor industries.

NoahAI News9/25/2025

«1...46 47 48...67 »